Association of APOE ε4 with cerebrospinal fluid protein and amyloid-β 42 levels in Alzheimer's disease

Abstract

Background

Alzheimer's disease (AD) is a neurodegenerative disease, with APOE ε4 as the most common genetic risk factor. This protein has been implicated in amyloid-β peptide (Aβ)-mediated pathological processes in patients with AD. However, the mechanism by which APOE ε4 regulates cerebrospinal fluid (CSF) protein levels and Aβ₄₂ concentration in CSF during the pathogenesis of AD has not been clarified.

Objective

To determine whether APOE ε4 contributes to the pathogenesis of AD by altering Aβ₄₂ concentrations and protein levels in CSF.

Methods

A total of 228 AD patients were enrolled and assigned into the APOE non-ε4 carrier group (146 patients) and the APOE ε4 carrier group (82 patients). The concentration of Aβ₄₂ and protein levels in CSF, as well as APOE genotypes were quantified. Subsequently, the association of APOE ε4 with CSF biomarkers was explored through multiple logistic regression analysis.

Results

In APOE ε4 carriers, CSF Aβ₄₂ (p = 0.016) and the protein (p = 0.040) levels in CSF were lower compared with levels in the non-carrier group. Moreover, APOE ε4 carriage was associated with lower levels of CSF Aβ₄₂ (odds ratio 0.998, 95% confidence interval 0.995–1.000, p = 0.048) and CSF protein (odds ratio 0.004, 95% confidence interval 0.000–0.224, p = 0.007) in APOE ε4 carriers.

Conclusions

APOE ε4 modulates the CSF protein levels and CSF Aβ₄₂ concentrations in AD patients. This indicates that the APOE ε4 genotype and CSF protein levels may help monitor the progression of AD.

Keywords

Alzheimer's disease apolipoprotein E amyloid-β 42 cerebrospinal fluid protein

Introduction

Alzheimer's disease (AD) is the most common neurodegenerative disease that contributes to cognitive decline in aged patients. The disease is characterized by excessive formation of senile plaque and neurofibrillary tangles, accumulation of extracellular neurotoxic amyloid-β (Aβ) peptide plaques, and intracellular neurofibrillary tangles enriched with hyperphosphorylated tau.¹ Studies have shown that AD is the most common cause of dementia, accounting for approximately 60–80% of all cases.² In the brain, Aβ₄₂ is negatively correlated with Aβ₄₂ concentrations in the cerebrospinal fluid (CSF), with reduced Aβ_42/40 in CSF considered a marker of AD. The concentration of CSF (p)Tau is increased in AD patients, and this correlates with intracerebral (p)Tau pathology. In addition, researchers have demonstrated that pTau is more specifically correlated with tau tangles in patients with AD than total tau.^3,4

Compelling evidence shows that the APOE ε4 allele is the most significant genetic risk factor influencing the development of late-onset AD (LOAD).⁵ APOE is a glycoprotein composed of 299 amino acids, with a molecular weight of 34 kilodaltons (kDa). This protein is primarily produced in hepatocytes and intrahepatic macrophages within peripheral tissues.⁶ Evidence indicates that the APOE protein is highly expressed in astrocytes, activated glial cells, vascular endothelial cells, choroid plexus cells, and in neurons to some degree under high stress.^7,8 In humans, three alleles of APOE have been reported: APOE2 (ε2), APOE3 (ε3), and APOE4 (ε4), and these alleles carry different disease risk levels. The APOE ε4 influences the risk of AD, exhibiting a gene-dose-dependent increase in the risk of homozygotes by up to 15-fold.⁹ Conversely, APOE ε2 reduces the risk of AD by nearly half and prolongs the patient's lifespan.¹⁰ Notably, APOE ε4 carriers have higher concentrations of Aβ deposits in the brain.^11,12 Besides forming Aβ plaques, APOE facilitates Aβ clearance via various mechanisms, including modulating receptor-mediated uptake and protease degradation. The interaction between APOE and pathological Aβ deposition has been postulated as the primary mechanism mediating the effects of APOE on AD development.

Notably, the APOE ε4 carriers exhibit low levels of Aβ in the CSF, suggesting that it can potentially contribute to disease progression.¹³ Data indicate that the APOE ε4 regulates Aβ in various pathological mechanisms.^14–16 However, the mechanisms linking APOE ε4, CSF protein levels and CSF Aβ₄₂ are not fully understood.

In this study, we analyzed and compared differences in CSF protein and Aβ₄₂ levels between APOE ε4 carriers and non-carriers. The aim was to determine whether these associations vary by age, gender, and cognitive function by leveraging Mini-Mental State Examination (MMSE). The findings of this study expand the current understanding into the mechanisms via which APOE ε4 contributes to AD pathology.

Methods

Participants

From January 2022 to October 2024, 228 consecutive participants were recruited from the cognitive impairment clinic of Tianjin Huanhu Hospital. The study was conducted in accordance with local clinical research regulations and informed consent was obtained all participants. In addition, the study followed the relevant national regulations and institutional policies, and followed the principles outlined in the Declaration of Helsinki. All patients completed the clinical scale assessment and agreed to undergo lumbar puncture examination. Among the participants, 168 participants fulfilled the biomarker criteria for AD. However, due to incomplete data and other related factors, 148 patients were ultimately included in the study. A detailed flowchart outlining the participant selection process is provided below.

Inclusion criteria

The inclusion criteria for patient enrollment was that all patients met the diagnostic guidelines for AD.¹⁷ Specifically, AD patients presenting with an insidious onset, a well-documented history of cognitive decline, and according to the 2018 NIA-AA AT(N) diagnostic framework for AD biomarkers, met the criteria for AD biomarker positivity.¹⁸

Exclusion criteria

Patients with increased risk of bleeding (such as thrombocytopenia, coagulopathy, or utilization of anticoagulant medications), a history of spinal surgery, inability to obtain sufficient quantities of CSF, and traumatic or hemorrhagic lumbar puncture, Malnutrition, neoplastic, dyslipidemia and hepatic disease, were excluded from the study. In addition, patients with mixed neurodegeneration conditions, particularly vascular dementia, dementia with Lewy bodies, frontotemporal lobar degeneration, and Parkinson's disease dementia co-occurrence, were excluded from the study.

Standardized collection of the clinical data

The eligible patients were comprehensively assessed following well-established protocols. Data were retrieved from patients’ records and using questionnaires. The data comprised variables such as years of education, current smoking and alcohol status (yes/no), hypertension, type 2 diabetes mellitus, body mass index (BMI), stroke and coronary heart disease. Various tests, including a MMSE, were applied.¹⁹ For each patient, cerebrospinal fluid biomarkers, including cerebrospinal protein, phosphorylated tau (p-tau181), and Aβ_1–42, as well as the ratio of Aβ_1–42 to Aβ_1–40 (refer to “Cerebrospinal fluid biomarkers” section) were recorded. Blood samples from were collected from all patients for APOE genotype testing, and they were categorized based on the number of APOE ε4 (0/non-APOE ε4 carrier, 1/APOE ε4 carrier).

The study was approved by the Medical Ethics Committee of Tianjin Huanhu Hospital (ID: 2019-40).

APOE genotyping

The Maxwell^®16 Instrument (Promega) and the Maxwell^®16 Blood DNA Purification Kit were used to extract genomic DNA from whole peripheral blood. Next, the APOE rs429358 and rs7412 regions were amplified through PCR utilizing Promega's GoTaq^® hot-start polymerase. The PCR products were purified using 0.5 mL centrifugal filter from Merck Millipore's Amicon^®Ultra. Cycle sequencing was performed using the AB Prism Big Dye Terminator Sequencing Kit 3.1 (Life Technologies), following the manufacturer's guidelines. Subsequently, the obtained sequence was purified utilizing a MicroSEQ™ID sequencing cleanup kit (Life Technologies) and loaded onto a 3500 gene analyzer (Life Technologies). The sequences were analyzed using Chromas software (Technelysium Pty Ltd).

Cerebrospinal fluid biomarkers

CSF samples were collected from the patients using a standardized protocol during a routine lumbar puncture diagnosis. All patients provided informed consent to participate in the study. The samples were collected in outpatient settings from 09:30 to 10:30 h.²⁰ The CSF samples were obtained into sterile polypropylene tubes and gently mixed to prevent gradient effects, for further measurement. The remaining CSF sample was centrifuged at 3000 rpm for 3 min and promptly aliquoted in equal volumes of 0.5 mL, and then immediately stored at −80°C or liquid nitrogen for subsequent analysis. The concentrations of p-tau181 and Aβ_1–42 in CSF were quantified using Lumipulse (Fujirebio) by a skilled technician who was blinded to the diagnosis or APOE genotype. In accordance with the accepted standards, CSF AD-like characteristics were defined based on the following predetermined cutoff values: Aβ_1–42 ≤ 650 pg/mL, p-Tau181 ≥ 58 pg/mL, or Aβ_1–42/Aβ_1–40<0.068.²⁰

The concentrations of protein in CSF were measured using the SPAplus^® turbidity analyzer and Freelite^® serum free light chain immunoassay, in line with the manufacturer's instructions.

Statistical analysis

The data were analyzed using IBM SPSS 27.0 software. Differences were considered statistically significant at p-value < 0.05.

The distribution of the data was determined using the Shapiro-Wilk test based on a p-value >0.05.

Normality tests were performed for continuous variables, and all variables followed a normal distribution. Continuous variables were presented as the mean value plus or minus the standard deviation, while categorical variables were expressed as numbers and percentages (n, %). The association and correlation between APOE genotype and biological markers and differences in CSF proteins among various APOE genotype classified by gender, age, and cognitive status was analyzed using the independent-samples t test. Categorical variables were compared using the Fisher's exact test. In addition, categorical variables of different APOE genotype were analyzed using the chi-square test. Finally, multivariate logistic regression analysis was conducted to explore the association between various APOE carriers and CSF biomarkers.

Results

Participant characteristics

A total of 228 patients diagnosed with AD were enrolled in this study (Figure 1), with 146 patients in the APOE non-ε4 carrier group (mean ± SD, age 62.90 ± 8.64 years, male: 81 [55.5%]) and 82 in the APOE ε4 carrier group (mean ± SD, age 64.12 ± 8.08 years old, male 44 [53.7%]). Among them, 125 (54.82%) were males and 103 (45.18%) were female. In addition, 47 (25.97%) patients were smokers, 21 (9.21%) consumed alcohol, 28 (12.28%) had hypertension, 19 (8.33%) had diabetes, 15 (6.58%) had coronary disease, and 14 (6.14%) had stroke. The demographic and clinical characteristics of all patients are presented in Table 1. Notably, there were no significant differences between the APOE ε4 carrier group and non-ε4 carrier group in terms of gender, age, smoking status, drinking status, and education level. Further comparison of clinical features between the two groups found no significant differences in cognitive status (as measured by MMSE score), hypertension, diabetes, coronary heart disease, stroke or BMI.

Figure 1.

Flowchart depicting the participant recruitment process.

Table 1.

Clinical and demographic characteristics of AD patients.

Characteristics	Non-ε4 carriersn = 146	ε4 carriersn = 82	p
Gender, n (%)
male	81 (55.5)	44 (53.7)	0.185
Age, y (mean ± SD)	62.90 ± 8.64	64.12 ± 8.08	0.262
MMSE, scores (mean ± SD)	15.28 ± 7.43	14.64 ± 6.67	0.521
MoCA, scores (mean ± SD)	10.52 ± 6.13	11.21 ± 5.48	0.316
BMI (mean ± SD)	23.10 ± 2.68	22.53 ± 3.05	0.055
Education, y (mean ± SD)	9.76 ± 4.15	10.70 ± 4.00	0.370
Alcohol, n (%)	14 (9.6)	7 (8.5)	0.758
Smoking, n (%)	31 (21.2)	16 (19.5)	0.792
Hypertension, n (%)	17 (11.6)	11 (13.4)	0.984
Diabetes, n (%)	14 (9.6)	5 (6.1)	0.226
Coronary disease, n (%)	10 (6.8)	5 (6.1)	0.826
Stroke, n (%)	8 (5.5)	6 (7.3)	0.579

MMSE: Mini-Mental State Exam; T2DM: type 2 diabetes mellitus; BMI: body mass index.

The association between APOE genotype and CSF biomarkers

In the AD cohort, the APOE ε4 carrier group demonstrated significantly lower levels of CSF Aβ₄₂ and total protein, as well as significantly higher levels of P-tau181, compared to the non-ε4 carriers. We analyzed the levels of CSF biomarkers between APOE ε4 carriers and non-ε4 carriers, and the results are presented in Table 2, the mean values of CSF Aβ₄₂ (p = 0.016) and CSF Aβ_42/40 (p = 0.035) were lower in the APOE ε4 carrier group than in the non-ε4 carrier group. The mean values of p-tau181 in the CSF of the APOE ε4-carrying group exceeded that of the APOE non-ε4-carrying group (p = 0.018). Compared with the non-ε4 carrier group, the CSF protein level was lower in the APOE ε4 carrier group (p = 0.040).

Table 2.

Analysis of the association of APOE genotype with CSF biomarkers in AD.

CSF-biomarkers	Non-ε4 carriersn = 146	ε4 carriersn = 82	p
CSF-Aβ₄₂	639.31 ± 479.11	434.02 ± 163.81	0.016*
p-tau181	85.20 ± 108.49	107.38 ± 85.94	0.018*
Aβ_42/40	0.06 ± 0.03	0.05 ± 0.02	0.035*
CSF protein	0.40 ± 0.14	0.34 ± 0.10	0.040*

APOE: apolipoprotein E; CSF: cerebrospinal fluid; Aβ₄₂: amyloid beta 42; p-tau181: hyperphosphorylation tau protein. *p < 0.05.

The association of APOE genotype with the CSF biomarkers in 138 age-matched, patients with non-Alzheimer's dementia was investigated. It was observed that, compared to the non-APOE ε4 carriers, the APOE ε4 carriers tended to have lower levels of CSF Aβ₄₂ and total protein, although the differences were not statistically significant. The APOE ε4 carriers tended to have higher Aβ_42/40 ratios and P-tau181 levels in CSF, it did not reach statistical significance (Table 3).

Table 3.

Analysis of the association between APOE genotype and CSF biomarkers in patients with non-Alzheimer's dementia.

CSF-biomarkers	Non-ε4 carriers(n = 48)	ε4 carriers(n = 19)	p
CSF-Aβ₄₂	512.8	466.88	0.572
Aβ_42/40	0.08	0.06	0.065
P-tau181	46.66	56.94	0.262
CSF protein	0.390	0.385	0.578

Regression analysis of the APOE genotype and levels of biomarkers in CSF

The correlation results between the APOE genotype and various CSF biomarkers, including CSF protein, CSF Aβ₄₂, CSF Aβ_42/40 ratio, and CSF p-tau181 is presented in Table 4. Moreover, in the model comprising CSF protein, CSF Aβ₄₂, CSF Aβ_42/40 ratio, and p-tau181 (hereafter referred to as the base model), APOE ε4 was strongly correlated with lower CSF protein levels (odds ratio, 0.006, 95%CI,0–0.308, p = 0.001). Furthermore, after adjusting for potential confounders such as sex, age, smoking, alcohol consumption, hypertension, type 2 diabetes, cerebral infarction, and heart disease in the final model, the presence of the APOE ε4 was significantly associated with reduced CSF Aβ₄₂ levels (odds ratio, 0.998; 95% CI, 0.995–1.000; p = 0.048). Furthermore, the correlation of CSF protein levels was stronger than previously reported (odds ratio, 0.004; 95% CI, 0.000–0.224; p = 0.007). However, no significant differences were observed in the association between APOE ε4 carriage and CSF Aβ_42/40 or p-tau181 levels.

Table 4.

Regression analysis of the APOE genotype and levels of biomarkers in CSF.

Biological markers	No. (%) of subjects		Basic model^a		Final model^b
	Non-ε4 carriers (n = 146)	ε4 carriers (n = 82)	OR95%CI	p	OR95%CI	p
CSF protein	130 (89.04)	76 (92.68)	0.006 (0.000–0.308)	0.001*	0.004 (0.000–0.224)	0.007*
CSF-Aβ₄₂	90 (61.64)	58 (70.73)	0.998 (0.996–1.000)	0.091	0.998 (0.995–1.000)	0.048*
Aβ_42/40	84 (64.61)	54 (65.85)	0.000 (0–2474.883)	0.186	0.000 (0–2376982.55)	0.415
p-tau181	100 (68.49)	63 (76.83)	1.001 (0.997–1.004)	0.712	1.001 (0.998–1.005)	0.502

APOE: apolipoprotein; CSF: cerebrospinal fluid.

incorporated cerebrospinal fluid (CSF) protein, CSF Aβ₄₂, CSF Aβ_42/40 ratio, and phosphorylated tau181 (p-tau181).

Adjusted for age, sex, education level, current smoking, alcohol, stroke, hypertension, type 2 diabetes mellitus and heart disease.

*p < 0.05.

Analysis of the association between APOE ε4 carriers and levels of protein in CSF

Difference in the APOE ε4 carriers and CSF protein levels were compared among genders (Figure 2(a)), age groups (Figure 2(b)), and cognitive statuses (Figure 2(c)). It was found that in female patients, the CSF protein levels of APOE ε4 carriers were significantly lower than those of non-APOE ε4 carriers (p = 0.004). In male patients, a trend toward lower CSF protein levels was observed in APOE ε4 carriers compared to non-APOE ε4 carriers; however, this difference was not statistically significant (p = 0.142).

Figure 2.

Analysis of the association between APOE ε4 carriers and levels of protein in CSF: (a) relationship between APOE and CSF protein in different gender, (b) relationship between APOE and CSF protein in different age, (c) relationship between APOE and CSF protein in different cognition levels. *p < 0.05; **p < 0.001. MMSE: Mini-Mental State Examination.

In patients aged 65–70 years, the CSF protein levels were lower in the APOE ε4 carrier group than in the non-APOE ε4 carrier group (p = 0.016). Similarly, for patients over 70 years old, the APOE ε4 carrier group exhibited lower CSF protein levels compared to the non-ε4 carrier group (p = 0.019).

Based on the MMSE scores, among the individuals with MMSE scores greater than 21 and between 10 and 20, APOE ε4 carriers showed significantly lower levels of CSF proteins than non-ε4 carriers (p = 0.024 and p = 0.004, respectively). However, in patients with MMSE scores below 10, the CSF protein levels were not significantly different between APOE ε4 carriers and non-ε4 carriers (p = 0.366).

Discussion

Key findings

This study found that the CSF levels of Aβ₄₂, the Aβ_42/40 ratio, and CSF protein were significantly lower in AD APOE ε4 carriers than in AD non-ε4 carriers (Table 2). Notably, this signature was not significant in age-matched, patients with non-Alzheimer's dementia (Table 3). Analysis of the correlation between APOE ε4 carriers and CSF biomarkers (Table 4) revealed a strong correlation between APOE ε4 carriers and decreased CSF Aβ₄₂ and CSF protein levels.

Moreover, the APOE ε4 carriers had lower concentrations of CSF Aβ₄₂, consistent with findings of prior studies, which revealed that Aβ₄₂ levels in the CSF were lower in APOE ε4 carriers than in non-ε4 carriers.^21–23

Mechanisms underlying reduced CSF Aβ₄₂

Research has shown that APOE is highly co-deposited with Aβ in amyloid plaques.²⁴ Furthermore, emerging amyloid pathology, which is characterized by marginally decreased CSF Aβ₄₂ or CSF Aβ₄₂ levels above the conventional threshold for amyloid positivity, may negatively affect the brain structure, function, and cognition.^25–28 Moreover, APOE ε4 carriers exhibited significantly higher and rapid amyloid deposition in the brain compared with non-APOE ε4 carriers.^16,29 Notably, the rate of Aβ clearance is modulated by its competitive binding to Aβ receptors, such as LDLR-associated protein 1 (LRP1), on astrocyte surfaces, thereby blocking Aβ uptake.³⁰ Evidence from prior investigations show that APOE ε4 can disrupt the integrity of the blood-brain barrier (BBB) via multiple pathways: APOE ε4 binds and interacts with the LRP1 receptor on the pericyte membrane³¹; as well as stimulates the loss and activation of the LRP1-dependent cyclophilin A-MMP9 pathway in pericytes and endothelial cells.³² In conclusion, the results indicated that Aβ₄₂ concentration in the CSF was significantly lower in APOE ε4 carriers.

Mechanisms underlying reduced CSF total protein

This analysis uncovered that the CSF protein concentration was lower in APOE ε4 carriers than in non-carriers. Currently, the association of APOE ε4 with CSF protein levels is a subject of debate. Previous research has shown that APOE ε4 carriers exhibit significantly increased protein levels in the CSF and a higher CSF-to-serum albumin ratio, suggesting a strong association between the APOE ε4 allele and increased BBB permeability.²³ However, evidence from research is inconsistent with this assertion, with some studies demonstrating that APOE ε4 may regulate CSF protein levels via other mechanisms besides compromising the integrity of the BBB. Other scholars have shown that APOE ε4 modulates the clearance and deposition of Aβ, altering other proteins in CSF.^33,34 Researchers have shown that APOE ε4 can induce mitochondrial dysfunction and neurodegenerative changes, potentially reducing CSF protein levels.^35,36 Furthermore, APOE ε4 can disrupt lipid transport and metabolism, compromising the normal physiological functions of glial cells such as astrocytes, leading to a decrease in CSF protein levels.³⁷ A previous investigation reported that APOE ε4 altered synaptic function and plasticity, increasing the risk of neurodegenerative disorders.¹⁵ Although advanced techniques were used for both blood APOE genotyping and cerebrospinal fluid biomarker detection, several practical limitations were encountered during the implementation. These included potential sampling errors, individual variability in sampling outcomes, and temporal constraints linked to sampling procedures. Additionally, we performed immunoassays, which may be affected by errors arising from reagent quality and instrument calibration issues, which affect the accuracy and precision of the results.

Influence of demographic and cognitive factors

We also explored the association between APOE ε4 carriers and CSF protein with regard to sex, age group, and cognitive status. Results indicated that CSF protein levels were significantly different between female APOE ε4 carriers and male non-ε4 carriers (Figure 2(a)). In prior studies, a negative correlation was observed between longitudinal changes in APOE and Aβ levels in female patients, which is consistent with our observations.³⁸ This may be due to sex-specific associations between APOE and AD pathology. For instance, it was demonstrated that CSF sex hormone-binding globulin (SHBG) can regulate bioactive testosterone and estradiol. Moreover, higher plasma SHBG levels were detected in AD patients, inactivating functionally neuroprotective testosterone and estradiol.³⁹ Furthermore, APOE expression level is modulated by estrogen,⁴⁰ as well as its receptor.⁴¹ Therefore, we hypothesize that the sex-specific association between CSF APOE and AD biomarkers may be partially influenced by female sex hormones.^38,42 Moreover, the APOE ε4 can trigger an inflammatory response in the female brain, activating microglia and astrocytes, thereby releasing inflammatory mediators, and causing neuronal damage.⁴³

Among individuals aged 65 years and older, APOE ε4 carriers had significantly lower concentrations of CSF protein compared to non-ε4 carriers (Figure 2(b)).

Available evidence indicates that APOE ε4 exacerbates age-related lipid metabolism disorders in the brain. Notably, aging is accompanied by a decline in physiological functions of enzymes (arachidonate cytidylyltransferase 2 (AACT2), etc.) and transporters (cellular cholesterol transporter ABCA1).⁴³ The presence of APOE ε4 further aggravates this decline, causing disruptions in intracellular and intercellular lipid transport and metabolism. This further compromises normal function of neurons and glial cells,⁴⁴ and interferes with protein synthesis, transport, and secretion in CSF,^45–47 resulting is reduced CSF protein levels.

Previous investigations revealed that aging influenced the capacity of APOE ε4 to promote the HMGB1 (critical pro-neuroinflammatory) translocation in the brain, leading to glial cell activation and gliosis.⁴⁸ This aggravates the inflammatory response, altering the expression and stability of proteins in the CSF. This can potentially induce neuronal damage, inhibit the synthesis and secretion of proteins, consequently reducing CSF protein levels.

Among patients with MMSE scores ranging from 10 to 20 and greater than 21, APOE ε4 carriers had significantly lower CSF protein levels compared with non-carriers (Figure 2(c)). Mechanistically, APOE ε4 contributed to cognitive decline, particularly during the early stages of the disease. Moreover, the Aβ₄₂ levels were decreased in patients with AD, and this phenomenon decreased as the condition progressed from very mild to moderate dementia.⁴⁹ In addition, APOE ε4 carriers exhibited lower CSF proteins at this stage, suggesting that decreased CSF proteins could serve as an early indicator of AD progression.

In this study, we investigated the association of APOE ε4 with the CSF protein and CSF Aβ₄₂ levels. These associations were particularly pronounced in women, individuals aged ≥65 years, and those with mild-to-moderate cognitive impairment (MMSE 10–20 or >21). Although the exact mechanisms are not clear, the observed reductions may reflect accelerated amyloid deposition and impaired protein homeostasis in APOE ε4 carriers.^50–52 Longitudinal studies combining receptor-binding assays and proteomics are advocated to clarify the pathways linking APOE ε4 to CSF protein dynamics. These findings underscore the critical role of APOE ε4 and CSF protein levels in the pathogenesis and progression of AD.

Limitation and outlook

Nevertheless, this study has some limitations that should be acknowledged. Firstly, this was a cross-sectional study with a limited sample size, which limited our capacity to confirm causality. Moreover, practical limitations of CSF sampling as a routine disease monitoring tool in AD patients should be acknowledged.

In future, large-scale, longitudinal studies should be performed to comprehensively investigate the relationship between the APOE ε4 and CSF protein levels, as well as the associated pathological mechanisms.

Conclusion

In conclusion, this study demonstrates that AD APOE ε4 carriers have reduced CSF Aβ₄₂ and CSF proteins relative to non-APOE ε4 carriers. Moreover, our results show that the APOE ε4 and CSF protein levels may serve as biomarkers for evaluating the progression of AD.

Footnotes

Acknowledgements

The authors have no acknowledgments to report.

ORCID iDs

Shiyu Fan

Yong Ji

Ethical considerations

The study was conducted in line with relevant national regulations and institutional policies, and followed the principles outlined in the Declaration of Helsinki. The study was approved by the Medical Ethics Committee of Tianjin Huanhu Hospital (ID: 2019-40).

Consent to participate

All participants in this study signed written consent forms.

Consent for publication

Not applicable

Author contribution(s)

Renyu Chen: Data curation; Writing – original draft.

Fang Yuan: Investigation; Resources.

Shuai Liu: Formal analysis; Resources.

Hao Wu: Data curation; Supervision.

Zhihong Shi: Writing – original draft.

Cihan Di: Conceptualization.

Shiyu Fan: Software; Validation.

Bing Liang: Conceptualization; Visualization.

Yong Ji: Methodology; Project administration.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China [grant number 82171182], Tianjin Scientific Research Projects in Key Areas of Traditional Chinese Medicine [grant number 2015017], Tianjin Science and Technology Plan Project [grant number 22ZYCGSY00840], Tianjin Municipal Education Commission Research projects[grant number 2023KJ060] and Tianjin Health Research Project [grant number TJWJ2023QN060 and TJWJ2022MS032].

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data availability statement

The data supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

Blennow

Hampel

Weiner

, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131–144.

Blennow

de Leon

Zetterberg

. Alzheimer's disease. Lancet 2006; 368: 387–403.

Olsson

Lautner

Andreasson

, et al. CSF And blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2016; 15: 673–684.

Sunderland

Linker

Mirza

, et al. Decreased beta-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094–2103.

Wightman

Jansen

Savage

, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 2021; 53: 1276–1282.

Huang

Weisgraber

Mucke

, et al. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J Mol Neurosci 2004; 23: 189–204.

Grubman

Chew

Ouyang

, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer's disease reveals cell-type-specific gene expression regulation. Nat Neurosci 2019; 22: 2087–2097.

Mahley

Huang

. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Neuron 2012; 76: 871–885.

Strittmatter

Saunders

Schmechel

, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 1977–1981.

10.

Corder

Saunders

Risch

, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180–184.

11.

O'Donnell

Rosand

Knudsen

, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000; 342: 240–245.

12.

Reiman

Caselli

Yun

, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752–758.

13.

Slot

RER

Kester

Van Harten

, et al. Apoe and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly. Neurobiol Aging 2019; 79: 101–109.

14.

Hashimoto

Serrano-Pozo

Hori

, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci 2012; 32: 15181–15192.

15.

Koffie

Hashimoto

Tai

, et al. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain 2012; 135: 2155–2168.

16.

Liu

Zhao

, et al. Apoe4 accelerates early seeding of amyloid pathology. Neuron 2017; 96: 1024–1032.e1023.

17.

McKhann

Knopman

Chertkow

, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263–269.

18.

Jack

Jr. Bennett

Blennow

, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018; 14: 535–562.

19.

Magni

Binetti

Bianchetti

, et al. Mini-mental state examination: a normative study in Italian elderly population. Eur J Neurol 1996; 3: 198–202.

20.

Fornari

Mori

Zoppi

, et al. Diagnostic accuracy of the five-word test for mild cognitive impairment due to Alzheimer's disease. Neurol Int 2022; 14: 357–367.

21.

Lautner

Insel

Skillbäck

, et al. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. Alzheimers Res Ther 2017; 9: 87.

22.

Lautner

Palmqvist

Mattsson

, et al. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry 2014; 71: 1183–1191.

23.

Libri

Silvestri

Caratozzolo

, et al. Association of APOE genotype with blood-brain barrier permeability in neurodegenerative disorders. Neurobiol Aging 2024; 140: 33–40.

24.

Namba

Tomonaga

Kawasaki

, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991; 541: 163–166.

25.

Insel

Mattsson

Donohue

, et al. The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement 2015; 11: 1171–1179.

26.

Insel

Mattsson

Mackin

, et al. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology 2016; 86: 1887–1896.

27.

Mattsson

Insel

Donohue

, et al. Predicting reduction of cerebrospinal fluid β-amyloid 42 in cognitively healthy controls. JAMA Neurol 2015; 72: 554–560.

28.

Mattsson

Insel

Nosheny

, et al. Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol 2014; 71: 725–734.

29.

Baek

Cho

Lee

, et al. Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer's disease. Alzheimers Res Ther 2020; 12: 140.

30.

Verghese

Castellano

Garai

, et al. Apoe influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci U S A 2013; 110: E1807–E1816.

31.

Nehra

Bauer

Hartz

AMS

. Blood-brain barrier leakage in Alzheimer's disease: from discovery to clinical relevance. Pharmacol Ther 2022; 234: 108119.

32.

Halliday

Rege

, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab 2016; 36: 216–227.

33.

Safieh

Korczyn

Michaelson

. Apoe4: an emerging therapeutic target for Alzheimer's disease. BMC Med 2019; 17: 64.

34.

Tsuang

Leverenz

Lopez

, et al. APOE Ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013; 70: 223–228.

35.

Mahley

. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med (Berl) 2016; 94: 739–746.

36.

Pires

Rego

. Apoe4 and Alzheimer's disease pathogenesis-mitochondrial deregulation and targeted therapeutic strategies. Int J Mol Sci 2023; 24: 778.

37.

Shi

, et al. Apoe4 impairs neuron-astrocyte coupling of fatty acid metabolism. Cell Rep 2021; 34: 108572.

38.

Liu

Song

, et al. The associations of cerebrospinal fluid ApoE and biomarkers of Alzheimer's disease: exploring interactions with sex. Front Neurosci 2021; 15: 633576.

39.

Xia

Song

, et al. Testosterone, estradiol, and sex hormone-binding globulin in Alzheimer's disease: a meta-analysis. Curr Alzheimer Res 2016; 13: 215–222.

40.

Stone

Rozovsky

Morgan

, et al. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol 1997; 143: 313–318.

41.

Wang

Irwin

Brinton

. Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. Proc Natl Acad Sci U S A 2006; 103: 16983–16988.

42.

Knapskog

Eldholm

Braekhus

, et al. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. BMC Geriatr 2017; 17: 210.

43.

Huang

Mahley

. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis 2014; 72 Pt A: 3–12.

44.

Yang

Wang

Zhang

, et al. Lipid metabolism and storage in neuroglia: role in brain development and neurodegenerative diseases. Cell Biosci 2022; 12: 106.

45.

García-Viñuales

Sciacca

MFM

Lanza

, et al. The interplay between lipid and Aβ amyloid homeostasis in Alzheimer's disease: risk factors and therapeutic opportunities. Chem Phys Lipids 2021; 236: 105072.

46.

Kurouski

. Elucidating the role of lipids in the aggregation of amyloidogenic proteins. Acc Chem Res 2023; 56: 2898–2906.

47.

Morgado

Garvey

. Lipids in amyloid-β processing, aggregation, and toxicity. Adv Exp Med Biol 2015; 855: 67–94.

48.

Koutsodendris

Blumenfeld

Agrawal

, et al. APOE4-promoted Gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell Rep 2023; 42: 113252.

49.

Riemenschneider

Schmolke

Lautenschlager

, et al. Cerebrospinal beta-amyloid ((1–42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 2000; 284: 85–88.

50.

. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10: 333–344.

51.

Tensaouti

Stephanz

, et al. Astrocytic ApoE underlies maturation of hippocampal neurons and cognitive recovery after traumatic brain injury in mice. Commun Biol 2021; 4: 1303.

52.

Zhao

Yamazaki

, et al. Author correction: APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. Nat Commun 2021; 12: 2707.

Association of APOE ε4 with cerebrospinal fluid protein and amyloid-β 42 levels in Alzheimer's disease

Abstract

Background

Objective

Methods

Results

Conclusions

Keywords

Introduction

Methods

Participants

Inclusion criteria

Exclusion criteria

Standardized collection of the clinical data

APOE genotyping

Cerebrospinal fluid biomarkers

Statistical analysis

Results

Participant characteristics

The association between APOE genotype and CSF biomarkers

Regression analysis of the APOE genotype and levels of biomarkers in CSF

Analysis of the association between APOE ε4 carriers and levels of protein in CSF

Discussion

Key findings

Mechanisms underlying reduced CSF Aβ42

Mechanisms underlying reduced CSF total protein

Influence of demographic and cognitive factors

Limitation and outlook

Conclusion

Footnotes

Acknowledgements

ORCID iDs

Ethical considerations

Consent to participate

Consent for publication

Author contribution(s)

Funding

Declaration of conflicting interests

Data availability statement

References

Mechanisms underlying reduced CSF Aβ₄₂